

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
MRI-1APPLICATION
NO.
09/855,817INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT Jochen Wolffgramm
CONFIRMATION NO. 4970FILING DATE
May 9, 2001

GROSS 1614

DEC 10 2001

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
SAJ	WO 97/03677	2/6/97	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
SAJ	Albrecht, K. and Lampe, D. 1992. Diagnostik und Therapie von akuten Drogennotfällen. Z. arztl. Fortbild. 85, pp. 701-707 (copy of English translation enclosed).
	Capasso, A. et al. 1995. Dexamethasone pretreatment reduces the psychomotor stimulant effects induced by cocaine and amphetamine in mice. Prog. Neuro-psychopharmacol. & Biol. Psychiat. 19, pp. 1063-1079.
	Capasso, A. et al. 1996. Dexamethasone selective inhibition of acute opioid physical dependence in isolated tissues. J. Pharmacol. Exp. Therapeut. 276, pp. 743-751.
	Capasso, A. et al. 1997. Dexamethasone inhibition of acute opioid physical dependence in vitro is reverted by anti-lipocortin-1 and mimicked by anti-type II extracellular PLA ₂ antibodies. Life Sci. 61, pp. 127-134.
	Ehrenreich, H. et al. 1997. OLITA: an alternative in the treatment of therapy-resistant chronic alcoholics. Eur. Arch Psychiatry Clin. Neurosci. 247, pp. 51-54.
	Mantsch, J.R. et al. 1998. Corticosterone facilitates the acquisition of cocaine self-administration in rats: opposite effects of the type II glucocorticoid receptor agonist dexamethasone. J. Pharmacol. Exp. Therapeut. 287, pp. 72-80.
SAJ	Montgomery, S.P. and Dafny, N. 1987. Cyclophosphamide and cortisol reduce the severity of morphine withdrawal. Int. J. Immunopharmacol. 9, pp. 453-457.


EXAMINER

DATE CONSIDERED

6/25/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
MRI-1APPLICATION
NO.
09/851,817INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT Jochen Wolffgramm
CONFIRMATION NO. 4970FILING DATE
May 9, 2001

GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER
INITIAL

Reddy, D.S. and Kulkarni, S.K. 1997. Neurosteroid coadministration prevents development of tolerance and augments recovery from benzodiazepine withdrawal anxiety and hyperactivity in mice. *Methods Find. Exp. Clin. Pharmacol.* 19, pp. 395-405.

Sass, H. et al. 1996. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. *Arch. Gen. Psychiatry* 53, pp. 673-680.

Sze, P.Y. 1977. The permissive role of glucocorticoids in the development of ethanol dependence and tolerance. *J. Drug Alcohol Dep.* 2, pp. 381-396.

Whitworth, A.B. et al. 1996. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. *Lancet* 347, pp. 1438-1442.

RECEIVED
DEC 10 2001
TECH CENTER 1800/2900

EXAMINER

DATE CONSIDERED

6/25/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.